The mechanism of action employed in GenSpera's lead investigational agent, mipsagargin, is unique in the way it destroys tumors. Our research has established proof-of-concept for the use of this innovative platform technology across a spectrum of drugs that precisely target different cancers.

Mipsagargin consists of a thapsigargin derivative, 12ADT, coupled to a peptide that helps solubilize the prodrug and prevents its internalization into cells until the peptide is removed.

The peptide recognizes an enzyme highly expressed on the surface of all cancer tumor vasculature and on prostate cancer cells. The enzyme recognizes and dissolves the peptide, releasing the active ingredient only within the tumor bringing about cell death.

This patented platform technology provides greater anti-tumor activity and minimizes side effects commonly observed with other therapies.